Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony S Mok

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Clinical Lung Cancer|July 31, 2016
Overview of Thoracic Oncology Trials in Cooperative Groups Around the GlobeAmeen Abdulla Salahudeen, Manali I Patel, Paul Baas, et al.
Pathology|February 27, 2024
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significantAlvin Ho-Kwan Cheung, Kit-Yee Wong, Shuk-Ling Chau, et al.
Drugs|December 17, 2020
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
Plos One|July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusShe-Juan An, Zhi-Hong Chen, Jian Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
The Oncologist|July 13, 2024
Calls to action on lung cancer management and researchMay-Lucie Meyer, Fred R Hirsch, Paul A Bunn, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung CancerYi-Long Wu, Shun Lu, You Lu, et al.
JTO Clinical and Research Reports|February 3, 2025
Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 ExpressionAlvin H K Cheung, Zeta Mui, Walter W Yeung, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy responseSangjoon Choi, Soo Ick Cho, Minuk Ma, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Clinical Lung Cancer|July 31, 2016
Overview of Thoracic Oncology Trials in Cooperative Groups Around the GlobeAmeen Abdulla Salahudeen, Manali I Patel, Paul Baas, et al.
Pathology|February 27, 2024
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significantAlvin Ho-Kwan Cheung, Kit-Yee Wong, Shuk-Ling Chau, et al.
Drugs|December 17, 2020
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
Plos One|July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusShe-Juan An, Zhi-Hong Chen, Jian Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating MutationsTony S Mok, Ying Cheng, Xiangdong Zhou, et al.
The Oncologist|July 13, 2024
Calls to action on lung cancer management and researchMay-Lucie Meyer, Fred R Hirsch, Paul A Bunn, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung CancerYi-Long Wu, Shun Lu, You Lu, et al.
JTO Clinical and Research Reports|February 3, 2025
Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 ExpressionAlvin H K Cheung, Zeta Mui, Walter W Yeung, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy responseSangjoon Choi, Soo Ick Cho, Minuk Ma, et al.
Pageof 5